Neuroendocrine tumor specialists.

Sue O’Dorisio, MD, PhD

Pediatric Oncologist           Neuroendocrine Cancer Program of the University of Iowa

Read Emily’s story an 8-year-old carcinoid survivor

 

Robert Fine, MD

Medical OncologyAssociate professor of medicine at New York Presbyterian Hospital-Columbia University Medical Center in New YorkExpert in CAPTEM therapy

Lead author of CAPTEM trial.

 

Renata D’Alpino Peixoto MD.

Medical OncologyHospital Alemão Oswaldo Cruz – Paulista, Sao Paulo, Brazil.

Expert in CAPTEM therapy.

 

Ocshner

New Orleans Louisiana Neuroendocrine Tumor Specialists.Louisiana State University/Ochsner Neuroendocrine Tumor Program.CAPTEM therapy.

 

Bad Berka Approach to PRRT Center

PRRT (Peptide Receptor Radionuclide Therapy)THERANOSTICS Center for Molecular Radiotherapy and Molecular ImagingENETS Center of ExcellenceZentralklinik Bad Berka 99437 Bad Berka, GermanyTel. +49 364 585 2200Fax +49 364 585 3515

An individualized approach to dosimetry and treatment, but also the view that patients should be administered lower amounts of radioactivity at more frequent and prolonged intervals (3-6 months in between therapies), rather than given a high dose of radiation at shorter intervals. The Bad Berka approach followed by Dr. Baum and his team sees NET cancer as a chronic disease to be treated over time.

 

Michael J. Demeure, MD, MBA (Endocrine Surgery)

Director, Rare Tumors Center. Precision Medicine.Program Director of Hoag Precision MedicineHoag Family Cancer Institute, Newport Beach, CAAddress 510 Superior Ave Ste 200G  Newport Beach, CA 92663 Phone: (949) 791-6767

 

Ranldoph Hecht, MD

Medical Oncology, GastroenterologyProfessor of Clinical Medicine, David Geffen School of Medicine, UCLA School of MedicineCarol and Saul Rosenzweig Chair in Cancer Therapies DevelopmentDirector, UCLA Gastrointestinal Oncology Program

Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has both clinical and research interests in the treatment of neuroendocrine tumors of the GI tract and works closely with UCLA surgeons, interventional radiologists, gastroenterologists, and endocrinologists as part of a multi-disciplinary group. He was the UCLA Principal Investigator (PI) for 4 NET trials (All 3 RADIANT trials and one IMC-A12) and has been the UCLA PI for more than 30 trials and overall PI for 14 multicenter (both US only and international) phase II and phase III trials.

 

David M. Liu, MD

Interventional RadiologyUnversity of British Columbia, Vancouver General Hospital757 Westwood Plaza, Suite 3-2125, 855 W 12th Ave CanadaTel: 604-875-4111, ext. 68612Tel: 604-875-5776 (appointments)

Specialist in Yttrium 90 treatment for liver metastases, radiofrequency ablation, cryoablation, chemoembolization, diagnostic imaging, and response.

 

Charles W. Nutting, DO 

Interventional RadiologyRadiology Imaging Associates10700 E. Geddes Street Suite 200 Englewood, CO 80112 Tel: 303-761-9190Email: charlie.nutting@riaco.com

Expert in liver radioembolization. Chemoembolization, Radiofrequency Ablation, Theraspheres, Sirspheres Connecticut.

 

Edward M. Wolin, MD

Medical OncologyDirector, Neuroendocrine Tumor Program, Montefiore Einstein Center for Cancer Care.Montefiore M-E Center for Cancer Care1521 Jarrett Place Bronx, NY 10461-2601Phone: (718) 862-884.

Dr. Wolin directs a large patient care and clinical research program, including a Multidisciplinary Weekly Carcinoid/Neuroendocrine Tumor Patient Management Conference. The renowned research program of Dr. Wolin is discovering treatments which are more effective and less toxic, including new somatostatin analogs, mTOR inhibitors, other types of biologic therapy. Cedars-Sinai has become a PRRT Center in the US, using 177Lu-DOTA0-Tyr3-Octreotate (Lutathera®) in the NETTER-1/AAA-III-01 study for carcinoid patients.

 

Nicholas J. DiBella, MD

Medical OncologyChairman, US Oncology, Hematology Research CommitteeChairman of the Board, Colorado Cancer Research ProgramPresident, Rocky Mountain Cancer CentersRocky Mountain Cancer Centers 1700 S. Potomac  Aurora, CO 80012 Tel: 303-418-7600

“In September 2006, Dr. Nick DiBella gave me my 25-year survival pin for having carcinoid with liver metastases for 25 years. Perhaps I can give hope to other carcinoid patients by telling my story.” Marilyn Thurston, Pueblo, CO

 

Riad Salem, MD, MBA

Interventional RadiologyNorthwestern University Medical School Department of Radiology675 North St. Clair Street Suite 800 Chicago, IL 60611 Tel: 312-695-5753

Comments: “Re: SirSpheres/Theraspheres procedures. After much research, Dr. Salem appears to be one of the most experienced interventional radiologists in the nation with this procedure and from his writings has had excellent results.” DF

Dr. Salem’s assistant is Patricia Jackson, 312-695-5753.

 

Matthew Kulke, MD

Medical OncologyDirector, Program in Neuroendocrine and Carcinoid Tumors., Harvard Medical School & Dana-Farber Cancer InstituteDana-Farber Cancer Institute, Boston,MA.44 Binney Street Dana 1220

We have established a robust clinical and translational research program at Dana-Farber Cancer Institute focused on neuroendocrine tumors. As part of our clinical research program, we evaluate over 200 neuroendocrine tumor patients annually and have studied numerous novel therapies for neuroendocrine tumor patients.

 

Steven T. Brower, MD

Surgical OncologyMedical Director of the Cancer Treatment and Wellness Center,Chief of Surgical Oncology, Professor of Surgery ISMMS at Englewood (NJ) Hospital and Medical Center.350 Engle St Englewood, NJ 07631Phone (201) 608-2800

Dr. Brower is board certified in general surgery and specializes in liver, pancreas, stomach, esophagus and rare gastrointestinal tumors. He utilizes both minimally invasive, robotic, and open techniques for complex cancer surgery.

 

Boris Kuvshinoff II, MD, MBA

Surgical OncologyChief Medical Officer at Roswell Park Comprehensive Cancer Center.Roswell Park Cancer Institute, Department of Surgical OncologyElm & Carlton Streets Buffalo, NYTel: 1-800-ROSWELL (1-800-767-9355)Email: boris.kuvshinoff@roswellpark.org

Clinical research interests include laparoscopic liver resection, radiofrequency ablation (RFA) of liver tumors, and multidisciplinary treatment of neuroendocrine (carcinoid) tumors.

 

Richard R.P. Warner, MD

Internal Medicine, GastroenterologyThe Mount Sinai Medical Center5 E. 98 Street Department of Medicine- Gastroenterology, 11th Floor New York, NY 10029 Tel: 212-241-4299Email: richard.warner@mountsinai.org

Dr. Warner is known internationally as an expert in carcinoid and related neuroendocrine tumors (NETs).He has vast experience in clinical practice and research in the diagnosis and management of these tumors and their syndromes. He has written scores of papers, reviews, and textbook chapters and conducts a very active consultative practice for all carcinoids/NETs.

 

The Penn Neuroendocrine Tumor Treatment Program (Penn Medicine) Center

Perelman Center for Advanced Medicine3400 Civic Center Boulevard Philadelphia, PA 19104 Tel: 800-789-PENN (7366)

Chemoembolization.

Penn has established itself as one of the only sites in the country with a unified program for both neuroendocrine tumor subtypes.

 

Ron C. Gaba, MD

Vascular and Interventional RadiologyNorthwestern Memorial Hospital, Chicago, IL1740 W Taylor st, (MC 931), Chicago, IL 60612Phone (312) 996 - 0242Email: rgaba@uic.edu

Chemoembolization.

http://www.jvir.org/article/S1051-0443(17)30471-2/pdf